Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials.
about
Intentional weight loss and dose reductions of anti-diabetic medications--a retrospective cohort studyManagement of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Standards of medical care in diabetes--2012Clinical Predictive Factors in Diabetic Kidney Disease ProgressionBasal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision makingCardiovascular importance of hyperglycemia and hypoglycemiaIntensification of insulin therapy in patients with type 2 diabetes mellitus: an algorithm for basal-bolus therapyDiabetic kidney disease: a report from an ADA Consensus ConferenceContributions of risk factors and medical care to cardiovascular mortality trendsGeldanamycin derivative ameliorates high fat diet-induced renal failure in diabetesUpdate on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.Comparison between the therapeutic effect of metformin, glimepiride and their combination as an add-on treatment to insulin glargine in uncontrolled patients with type 2 diabetesStandards of medical care in diabetes--2013Conformational dynamics of insulin.Optimal therapy of type 2 diabetes: a controversial challengeEvidence-based clinical use of insulin premixturesLow socioeconomic status is associated with increased risk for hypoglycemia in diabetes patients: the Diabetes Study of Northern California (DISTANCE).Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach.Identifying and meeting the challenges of insulin therapy in type 2 diabetes.We can change the natural history of type 2 diabetes.Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association.Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.Role of premixed insulin analogues in the treatment of patients with type 2 diabetes mellitus: a narrative reviewEffect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus.Understanding the influence of psychological and socioeconomic factors on diabetes self-care using structured equation modelingShared decision making in type 2 diabetes with a support decision tool that takes into account clinical factors, the intensity of treatment and patient preferences: design of a cluster randomised (OPTIMAL) trial.Glycemic management in patients with coronary artery disease and prediabetes or type 2 diabetes mellitus.Predictors of response in initial users of metformin and sulphonylurea derivatives: a systematic review.Individualizing HbA1c targets for patients with diabetes: impact of an automated algorithm within a primary care network.Attainment of multifactorial treatment targets among the elderly in a lipid clinicIntensive diabetes therapy and glomerular filtration rate in type 1 diabetes.Quality of Diabetes Care: The Challenges of an Increasing Epidemic in Mexico. Results from Two National Health Surveys (2006 and 2012).Metabolic memory and individual treatment aims in type 2 diabetes--outcome-lessons learned from large clinical trials.Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetesPrevalence of and Racial Disparities in Risk Factor Control in Older Adults With Diabetes: The Atherosclerosis Risk in Communities StudyPrioritization of care in adults with diabetes and comorbidity.Patient preference and tolerability of a DPP-4 inhibitor versus a GLP-1 analog in patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week, randomized, multicenter, crossover study.Meeting individualized glycemic targets in primary care patients with type 2 diabetes in Spain.Insulin analogs for the treatment of diabetes mellitus: therapeutic applications of protein engineering.Diabetes treatment intensification and associated changes in HbA1c and body mass index: a cohort study.
P2860
Q21560863-238A657B-AD3D-4634-800C-B5CFE734E702Q22241288-9D3AEB73-94AF-447B-B0BB-6A066F502497Q24632533-DE95165E-5847-435B-9A05-BF8CC87D8715Q26749494-C4E7C8B1-AB36-4754-AEE1-D178D112BE9AQ26992979-181F9D87-3E43-4005-B422-9199D40C9485Q26999390-0C691685-0F3F-4CF7-BFC4-16DD6731C927Q27001931-502A9F69-48B5-4D76-A334-098B45814451Q27012546-DA677677-6F9E-4469-B0EF-4C734CD5BC50Q27012592-8E13392A-6E8C-423F-A617-A9F6AD4E1848Q27307854-79693CD0-4AC9-4830-95BB-6B39CFB9E74EQ27687851-3A64189D-4384-4B09-8648-B1F822E52C95Q28540655-FAB35C05-77FD-431F-B574-F9B08618C983Q29620309-5F888B53-7701-418E-B66A-34A5B7658CF6Q30417406-D4019E6D-4365-441F-94E3-DEACA4131B5AQ33577712-3DA52BD4-3386-4C7F-BA3A-0BFFEC546B32Q33591271-79E55A30-9B2C-47C6-8716-FD94EE6AFD3AQ33664937-83804144-FA52-43DE-9B32-DCCA5A95F9F5Q33805824-F88BD95B-B570-4C31-AFE3-99A079A3666DQ33863413-4452770B-6EE7-41E5-BE0D-54DB2D0765A8Q34219402-96DFB974-BF05-434C-BDAF-3E0C36C5E7FBQ34224601-0F8BD747-12BD-4105-9DD5-72EB9BC68C16Q34457919-25363439-53BB-4D86-96B9-7EDDC006F7E1Q34851203-A823BD96-A180-4CB0-8F5C-8C6863285A75Q34988073-B61A71EE-4BC1-4190-8699-D1B5DAC04875Q35039688-A1BCF2EB-8F0B-4F31-867F-346CCD076054Q35206656-63BAB857-9C6A-4073-A00D-0269203E3C1AQ35466028-B31B1A32-81CC-47E7-8398-73176A548531Q35541829-9611C78E-CC38-4117-94D5-DA3BEB190594Q35587902-C12B35A7-64AC-4690-814E-4F66EFA6969EQ35697336-BCDA76C2-22A7-46A9-85C9-D92A43275A61Q35721420-E0CDB93E-4B66-4833-8CD4-F8648C4A03CFQ35731414-E3DF0F1B-5844-45B3-9D8F-90C29CB91AC7Q35760316-E804DC2A-A1BD-4C61-9271-CEE295558D77Q35766301-D9620B4B-7322-4A25-94BC-81B7BC9360B2Q35769481-766D4954-7288-4286-8E96-A180EB7A5559Q35798114-66B8E5DF-43DF-4CC4-AD89-D8BA252B9306Q35916889-900640BE-9C98-4F22-BF4D-1F0DBFF2DFD5Q35926547-7018B3BC-23C5-4BED-AF31-17E32D53EF7FQ35988978-E606D19C-1CFA-4491-9378-A879CB8949A9Q36038607-1FB6D09B-B233-4941-89DD-90723FFF1AE5
P2860
Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Individualizing glycemic targe ...... ons of recent clinical trials.
@en
Individualizing glycemic targe ...... ons of recent clinical trials.
@nl
type
label
Individualizing glycemic targe ...... ons of recent clinical trials.
@en
Individualizing glycemic targe ...... ons of recent clinical trials.
@nl
prefLabel
Individualizing glycemic targe ...... ons of recent clinical trials.
@en
Individualizing glycemic targe ...... ons of recent clinical trials.
@nl
P2093
P1476
Individualizing glycemic targe ...... ons of recent clinical trials.
@en
P2093
Etie Moghissi
Faramarz Ismail-Beigi
Irl B Hirsch
Margaret Tiktin
Saul Genuth
Silvio E Inzucchi
P304
P356
10.7326/0003-4819-154-8-201104190-00007
P407
P577
2011-04-01T00:00:00Z